Oxybutynin Chloride NDC 72888-031

NDC codes

FDA NDC Directory

Product NDC (as listed)72888-031Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72888-0031Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72888-031-01	72888003101	100 TABLET, EXTENDED RELEASE in 1 BOTTLE (72888-031-01)Marketed from Oct 27, 2020
72888-031-05	72888003105	500 TABLET, EXTENDED RELEASE in 1 BOTTLE (72888-031-05)Marketed from Jul 10, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Oxybutynin Chloride
Generic name (nonproprietary): oxybutynin chloride
Active ingredients: Oxybutynin chloride — 10 mg/1
Dosage form: Tablet, Extended release
Route: Oral
Labeler: Advagen Pharma Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 214415
Marketing start: Oct 27, 2020
Listing expires: Dec 31, 2027
Other FDA classes: Cholinergic Muscarinic Antagonists (Mechanism)
Identifiers: Product ID 72888-031_48596af5-29b7-ab6c-e063-6394a90a1276SPL ID 48596af5-29b7-ab6c-e063-6394a90a1276SPL set ID 7bd31561-4c76-4c6b-819b-492549886673RxCUI 863619, 863628, 863636UNII L9F3D9RENQUPC 0372888031057, 0372888032016, 0372888030012, 0372888032054, 0372888031019, 0372888030050
Pharmacologic class: Cholinergic Muscarinic Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472888003101 followed by a unit qualifier and the quantity

Package 72888-0031-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 14, 2026.

Indications (excerpt from the label)

Oxybutynin chloride is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin chloride extended-release tablets are also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida). Oxybutynin chloride extended-release tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 ) Oxybutynin chloride extended-release tablets are also indicated for the treatment of pediatric patients aged …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 214415

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 214415
Product	Strength	Form · route	Labeler	Product NDC
Oxybutynin Chloride	Oxybutynin chloride 5 mg/1	Tablet, Extended releaseOral	Advagen Pharma Limited	72888-030
Oxybutynin Chloride	Oxybutynin chloride 15 mg/1	Tablet, Extended releaseOral	Advagen Pharma Limited	72888-032